Buy Crypto
Markets
Spot
FuturesBTC
Earn
Event Center
Rewards Hub
More
100%+ PoR
KTTA

Pasithea Therapeutics Corp. (KTTA)

NASDAQ
$0.43
-$0.07
(-14.68%)
After-Hours

Last updated: ⁦2026-11-17 21:11:00⁩. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.

Summary

Pasithea Therapeutics Corp. (KTTA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.43, with a market capitalization of $17.44M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.28 to $2.06. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

$17.44M

$0.51

$0.53

$0.42

$0.50

2.08M

672.69K

--

$2.06

$0.28

--

--

Pasithea Therapeutics Corp. (KTTA) After-Hours Stock Price

Pasithea Therapeutics Corp. (KTTA) is trading at $0.43 in after-hours trading as of 2026-11-17 20:54:51, unchanged from the regular-session close of $0.43.

After-hours trading shows how investors are pricing KTTA after the regular session closes. The current after-hours price is near the regular-session close, indicating neutral after-hours sentiment.

Pasithea Therapeutics Corp. (KTTA) 7-Day Stock Price Change

Over the past seven days, Pasithea Therapeutics Corp. (KTTA) moved from $0.58 to $0.43, representing a decline of 25.71% ($0.15).

The stock traded between $0.42 and $0.61 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.

The average daily volume was 701.58 thousand shares, down versus the previous seven-day period, indicating lower trading activity.

KTTA 52-Week Price Position

Position in Range: 8.4%

52W Low$0.28
52W High$2.06

KTTA is currently trading at $0.43, placing it 8.4% of the way from its 52-week low of $0.28 to its 52-week high of $2.06. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Pasithea Therapeutics Corp. (KTTA)?

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Pasithea Therapeutics Corp. Information

Industry
PHARMACEUTICAL PREPARATIONS
Employees
5
Exchange
NASDAQ
Company Website

KTTA News

Latest news related to Pasithea Therapeutics Corp. and KTTA stock.

  • Benzinga

    HC Wainwright & Co. Maintains Buy on Pasithea Therapeutics, Raises Price Target to $4

    HC Wainwright & Co. analyst Sara Nik maintains Pasithea Therapeutics (NASDAQ:KTTA) with a Buy and raises the price target from $3 to $4.

    Read Full Article
  • Benzinga

    Pasithea's PAS-004 Shrinks Skin Tumors in All 15 Evaluable Patients

    Pasithea Therapeutics shares positive Phase 1/1b NF1 clinical data for PAS-004, showing tumor reductions and clean safety ahead of Phase 2.

    Read Full Article
  • Benzinga

    Pasithea’s PAS-004 Reduces Cutaneous Neurofibromas In All 15 Evaluable Participants, 41% Median Best Reduction, 46% At Planned Phase 2 Doses, With No Treatment-Related Serious Adverse Events

    All participants showed cutaneous neurofibroma (cNF) reductions: All 15 evaluable participants had reductions in target cNF surface area, with a median best reduction of 41% across all doses and 46% at doses planned for

    Read Full Article
  • Massive

    Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference

    Pasithea Therapeutics announced positive Phase 1/1b clinical data for PAS-004, its oral MEK inhibitor candidate, showing substantial reductions in cutaneous neurofibroma size (median 41-46% reduction) and early activity in plexiform neurofibromas across all participants. The drug demonstrated a favorable safety profile with no serious adverse events or treatment-related discontinuations. The FDA has cleared the IND for a Phase 2 randomized, placebo-controlled trial in approximately 200 adults with NF1-associated cutaneous neurofibromas.

    Read Full Article

Ways to Trade KTTA at MEXC

KTTA MEXC RealStocks

Own real KTTA shares through MEXC's regulated brokerage partner.


Suitable for long-term holding.

  • Own the actual shares
  • Receive dividends and voting rights
  • Buy fractional shares starting at $1

How to Buy Pasithea Therapeutics Corp. (KTTA) Stock on MEXC

Eligible investors can buy real shares of Pasithea Therapeutics Corp. (KTTA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account
Step 1: Open and Verify Your RealStocks Account
Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.
Step 2: Transfer USDT to Your RealStocks Account
Step 2: Transfer USDT to Your RealStocks Account
Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.
Step 3: Search for KTTA and Place Your Order
Step 3: Search for KTTA and Place Your Order
Open the RealStocks trading page and search for KTTA. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Pasithea Therapeutics Corp. (KTTA) stock price today?
Pasithea Therapeutics Corp. (KTTA) is currently trading at $0.43, down 14.68% ($0.07) from the previous close of $0.50. Intraday prices update in real time during regular trading hours.
2.Is KTTA stock going up or down today?
As of 2026-11-17 20:54:51, KTTA is trading at $0.43, down 14.68% ($0.07) from its previous close of $0.50. The stock has traded between $0.42 and $0.53 during today’s regular session. Past price movements do not guarantee future results.
3.What is KTTA pre-market price?
As of 2026-11-17 20:54:51, KTTA is trading at $0.49 in pre-market trading, down 3.00% ($0.02) from the previous close of $0.50. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.
4.What is KTTA after-hours price?
As of 2026-11-17 20:54:51, KTTA is trading at $0.43 in after-hours trading, unchanged from the regular-session close of $0.43. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.
5.Is KTTA stock trading now?
KTTA trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.
6.Where does KTTA sit relative to its 52-week high and low?
Over the past 52 weeks, KTTA has traded between a low of $0.28 and a high of $2.06. At $0.43, the stock is positioned 8.4% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.
7.What sector is Pasithea Therapeutics Corp. in?
Pasithea Therapeutics Corp. (KTTA) operates in the PHARMACEUTICAL PREPARATIONS sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.
8.What is Pasithea Therapeutics Corp.'s market capitalization and where is it listed?
Pasithea Therapeutics Corp. is listed on the NASDAQ exchange with a market capitalization of $17.44M. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.
9.How is KTTA valued in terms of P/E ratio and EPS?
KTTA trades at a P/E ratio of --, based on trailing-twelve-month EPS of $-0.74. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.
10.Does Pasithea Therapeutics Corp. pay a dividend?
Pasithea Therapeutics Corp. pays an indicated annual cash dividend of $0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.

Explore More US Stocks

Largest Market Cap

See US stocks with the highest market capitalization

Top 5 Cryptocurrencies

Explore the cryptocurrencies with the highest market capitalization

Compliance Disclosure and Data Source

Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to KTTA, including Stocks, Tokenized Stocks, and Stock Futures.

Disclaimer

The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.

Search Stocks

KTTA Stock Calculator

Estimate the value between KTTA shares and USD.

KTTA Shares to USD

KTTA Shares
KTTA
KTTA
USD
USD
USD

1.00 KTTA shares = 0.43 USD

Calculations are estimates based on the latest available price and are for reference only.